![Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet](https://www.thelancet.com/cms/attachment/736a79af-cfc6-4ee1-8fc8-655362a05949/gr1_lrg.jpg)
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet
![AMAL CLOONEY: SHE DOESN'T LOOK LIKE A LAWYER – Janet Charlton's Hollywood, Celebrity Gossip and Rumors AMAL CLOONEY: SHE DOESN'T LOOK LIKE A LAWYER – Janet Charlton's Hollywood, Celebrity Gossip and Rumors](https://i0.wp.com/janetcharltonshollywood.com/images/2022/09/BGUS_2454896_001.jpeg?ssl=1)
AMAL CLOONEY: SHE DOESN'T LOOK LIKE A LAWYER – Janet Charlton's Hollywood, Celebrity Gossip and Rumors
![Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study - The Lancet HIV Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study - The Lancet HIV](https://www.thelancet.com/cms/attachment/244fa4cf-c08b-4259-bbeb-105e440c6e3f/gr1_lrg.jpg)
Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study - The Lancet HIV
![Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial - The Lancet Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/0af83eda-db0a-4a26-8f88-e4384c0333f6/gr1.jpg)
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial - The Lancet
![Pharmaceutics | Free Full-Text | Precision Nanotoxicology in Drug Development: Current Trends and Challenges in Safety and Toxicity Implications of Customized Multifunctional Nanocarriers for Drug-Delivery Applications Pharmaceutics | Free Full-Text | Precision Nanotoxicology in Drug Development: Current Trends and Challenges in Safety and Toxicity Implications of Customized Multifunctional Nanocarriers for Drug-Delivery Applications](https://www.mdpi.com/pharmaceutics/pharmaceutics-14-02463/article_deploy/html/images/pharmaceutics-14-02463-g001.png)